Cryo-Cell International, Inc. (CCEL) Stock Price & Analysis
Cryo-Cell International, Inc. (CCEL) — MoonshotScore 33/100 (Weak band), calculated Nov 18, 2026. Price $4.15 (-0.48%), as of the Nov 19, 2026 trading session; market cap $33.5M.
Educational signal · not a buy or sell recommendation · How to read this
Cryo-Cell International, Inc. · CCEL · NASDAQ
Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, focusing on umbilical cord blood and tissue stem cells. They offer preservation services and manufacture the PrepaCyte CB processing system, catering to expectant parents and healthcare professionals.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cryo-Cell International (CCEL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but stalling growth — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Cheap; Growth Durability: Shrinking; Momentum: Surging.
- quarterly revenue $8M (Q3 FY2026, quarter ended Aug 2026)
- EPS beat 7 of the last 8 reports
- Altman Z -0.10 · Piotroski F 6
Holding back: soft growth
Helping: business quality, balance-sheet strength, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 33 | Weak | |
| 33 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.15 | |
| Change on the day | -0.48% | |
| 52-week range | $2.72 – $5.45 | |
| Market capitalisation | $33.5M | — |
| Shares traded on the day | 11.6K |
Price & events
Other perspectives
Council score for Cryo-Cell International (CCEL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cryo-Cell International (CCEL), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Cryo-Cell International, Inc. (CCEL) is listed on NASDAQ. It employs 74 people and is led by David Portnoy. In Q3 FY2026 it reported revenue of $8M and net income of $1M. The market values it at $33.5M.
What do the latest results show for Cryo-Cell International (CCEL)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $8M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $8M | $1M | $0.16 (diluted) |
| Q2 FY2026 | $8M | $554,586 | $0.07 (diluted) |
| Q1 FY2026 | $8M | $47,108 | $0.01 (diluted) |
| Q4 FY2025 | $8M | -$5M | -$0.58 (diluted) |
What are the financial strengths and risks for Cryo-Cell International (CCEL)?
Short answer · as of
The MoonshotScore pillars rate business quality, balance-sheet strength, an attractive price, positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z -0.10 · Piotroski F 6. Trailing ratios: ROE 15.8% · ROA -4.5% · current ratio 0.86 · earnings yield -7.2% · free-cash-flow yield 11.9%.
How does Cryo-Cell International compare with its peers?
Short answer
Cryo-Cell International's score ranks tied for 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $34.35 Nov 19, 2026 | $1.32B | 93 5-pillar Nov 18, 2026 | |
| $8.91 Nov 19, 2026 | $1.22B | 92 5-pillar Nov 18, 2026 | |
| $29.65 Nov 18, 2026 | $1.47B | 80 5-pillar Nov 18, 2026 | |
| $6.43 Nov 19, 2026 | $88.0M | 73 5-pillar Nov 18, 2026 | |
| $34.09 Nov 19, 2026 | $1.20B | 68 5-pillar Nov 18, 2026 | |
| $94.32 Nov 19, 2026 | $1.41B | 63 5-pillar Nov 18, 2026 | |
| $3.90 Nov 19, 2026 | $289M | 59 5-pillar Nov 18, 2026 | |
| $1.61 Nov 19, 2026 | $227M | 52 5-pillar Nov 18, 2026 | |
| $1.05 Nov 19, 2026 | $7.01M | 43 5-pillar Nov 18, 2026 | |
| $0.84 Nov 19, 2026 | $27.3M | 39 5-pillar Nov 18, 2026 | |
| Cryo-Cell International (CCEL) — this page | $4.15 | $33.5M | 33 |
| $0.65 Nov 19, 2026 | $48.4M | 33 5-pillar Nov 18, 2026 | |
| $1.86 Nov 19, 2026 | $385M | 31 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 27, 2026
- Transactions
- 6
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CCEL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CCEL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Cryo-Cell International (CCEL)
These answers are editorial: 1 of these 9 answers is drawn from the CCEL research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CCEL?
CCEL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, focusing on umbilical cord blood and tissue stem cells.
Is CCEL a good stock to buy?
Stock Expert AI does not rate CCEL buy, sell or hold. Cryo-Cell International, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CCEL stock price today?
The last price recorded for Cryo-Cell International, Inc. (CCEL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about CCEL stock?
Analyst coverage of Cryo-Cell International, Inc. (CCEL) is limited due to its small market capitalization. Key valuation metrics, such as price-to-earnings ratio, may not be readily available or meaningful due to the company's negative profit margin.
What are the key factors to evaluate for CCEL?
Cryo-Cell International, Inc. (CCEL) holds a MoonshotScore in the low range. Expansion into New Therapeutic Applications: The increasing research and development in regenerative medicine presents an opportunity for Cryo-Cell International to expand the therapeutic applications of stored cord blood and tissue. Not financial advice.
How frequently does CCEL data refresh on this page?
CCEL's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CCEL's recent stock price performance?
Cryo-Cell International, Inc. (CCEL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the niche market of cord blood and tissue preservation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CCEL overvalued or undervalued right now?
Cryo-Cell International, Inc. (CCEL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CCEL?
Fractional-share availability for Cryo-Cell International, Inc. (CCEL) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com